Scientists from the University of Bristol have designed a new synthetic glucose binding molecule platform that brings us one step closer to the development of the world's first glucose-responsive insulin which, say researchers, will transform the treatment of diabetes.

Researchers at the University of Zurich have determined the three-dimensional structure of a receptor that controls the release of calcium from bones. The receptor is now one of the main candidates for developing new drugs to treat osteoporosis.

The tissues in our bodies largely are made of fluid. It moves around cells and is essential to normal body function. In people who have glioblastoma, the deadliest form of brain cancer, this fluid has a much higher pressure, causing it to move fast and forcing cancer cells to spread. Researchers may have found a solution to stopping this inevitable cancer cell spread.

In this article, we explore two novel high-throughput analytical methods based on liquid chromatography-mass spectrometry (LC-MS) analysis that can augment early drug screening and biomarker detection in the clinic.

The development of new in vitro models to replace in vivo testing has already proven quite successful for certain targets. Among these are models of the immune system and human skin, while in vitro cardiac arrhythmia models are poised to emerge in the near future. Despite this clear progress, an efficient model for liver organ toxicity testing still remains elusive.

To achieve regulatory compliance and authorization for sale in Europe, every medical device must be supported by a Clinical Evaluation Report which documents the entire clinical evaluation process. Read on for recommendations on how manufacturers can keep up with the changing regulation landscape.

The rate at which new drugs are discovered is in decline, and computer-aided drug design has not produced the radical change in the success of candidate drugs the pharma industry anticipated. Artificial intelligence (AI)-based approaches are the new hope for revolutionizing the drug discovery process. But are these, as computer-aided drug design was, an over-hyped time bomb waiting to be found out? Or is it truly a revolution on the cusp of realizing its promise?

As part of the host-pathogen arms race, viruses are continually evolving to evade the host immune response, be it from previous infection or immunity acquired through vaccination. Here we take a look at the processes of antigenic drift and antigenic shift.

Changes to the complex of DNA and the proteins that form chromatin are important drivers in many cancers. We explore the challenges and progress in the development of new therapies targeting epigenetic regulators.